Pliant Therapeutics (PLRX) Projected to Release Quarterly Earnings on Thursday

Pliant Therapeutics (NASDAQ:PLRX) is expected to issue its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Pliant Therapeutics to announce earnings of ($0.37) per share for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

Pliant Therapeutics (NASDAQ:PLRX) last announced its earnings results on Tuesday, August 11th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.02). On average, analysts expect Pliant Therapeutics to post ($1.42) EPS for the current fiscal year and ($1.53) EPS for the next fiscal year.

Pliant Therapeutics Price Performance

Shares of Pliant Therapeutics stock opened at $0.89 on Thursday. Pliant Therapeutics has a 1-year low of $0.83 and a 1-year high of $1.81. The company has a market capitalization of $55.10 million, a PE ratio of -0.60 and a beta of 1.27. The business has a 50-day moving average of $1.05 and a 200-day moving average of $1.17.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on PLRX shares. Wall Street Zen raised Pliant Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, September 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pliant Therapeutics in a research report on Thursday, October 15th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $3.00.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases. The company’s research is centered on integrin biology, a field involving proteins that regulate cell communication and tissue remodeling. Pliant aims to develop medicines that address the underlying processes that drive fibrosis in organs such as the lungs and liver.

Pliant’s lead investigational product is bexotegrast, an oral, selective inhibitor of the integrins αvβ1 and αvβ6.